Neo Ivy Capital Management’s Charles River Laboratories CRL Stock Holding History

Neo Ivy Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,248	Closed	-$249K	–	373
2025 Q4	$249K	Buy	1,248 +786	+170%	+$143K	0.04%	262
2025 Q3	$72.3K	Buy	462 +270	+141%	+$42.9K	0.02%	333
2025 Q2	$29.1K	Buy	+192	New	+$25.6K	0.01%	317
2025 Q1	–	Sell	-1,956	Closed	-$361K	–	314
2024 Q4	$361K	Sell	1,956 -2,946	-60%	-$567K	0.07%	180
2024 Q3	$966K	Buy	+4,902	New	+$1.02M	0.31%	127
2023 Q4	–	Sell	-1,104	Closed	-$216K	–	323
2023 Q3	$216K	Buy	+1,104	New	+$227K	0.09%	223
2022 Q4	$465K	Buy	+2,136	New	+$466K	0.31%	164

Other funds holding CRL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Neo Ivy Capital Management's CRL Position: Q1 2026 in Review

Neo Ivy Capital Management sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 1,248 shares — an estimated $249K sold.

Neo Ivy Capital Management first reported a position in CRL in Q4 2022 and held it in 7 quarters. The position peaked at $966K in Q3 2024. 560 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Neo Ivy Capital Management reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
Neo Ivy Capital Management sold 1,248 Charles River Laboratories shares in Q1 2026, an estimated $249K.
Neo Ivy Capital Management first reported a position in Charles River Laboratories in Q4 2022 and held it in 7 quarters.
Neo Ivy Capital Management's Charles River Laboratories position peaked at $966K in Q3 2024.
560 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.